Study guide
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP
UEMS European Board of Dermatovenereology Diploma Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Structure, Eligibility & Examination Regulations
1.1 EBDVD Exam Format, Session Timing & Scoring Rules 1.2 Eligibility Routes, Application Requirements & Re-take Regulations 1.3 UEMS-EBDV Governance, European Training Requirements & Diploma Recognition
2 Chapter 2: Dermatologic Terminology, Lesion Morphology & Skin Biology
2.1 Skin Anatomy, Epidermal Biology & Barrier Function 2.2 Primary & Secondary Lesion Morphology 2.3 Cutaneous Immunology & Pathophysiological Reaction Patterns
3 Chapter 3: Dermatopathology & Diagnostic Procedures
3.1 Biopsy Selection, Processing & Special Staining Techniques 3.2 Major Histopathologic Patterns & Tissue Reaction Types 3.3 Direct & Indirect Immunofluorescence Microscopy
4 Chapter 4: Epidemiology, Photobiology & Occupational Dermatology
4.1 Epidemiological Principles & Cutaneous Disease Burden 4.2 Photobiology & Photoprotection 4.3 Occupational Dermatoses & Contact Sensitisation Surveillance
5 Chapter 5: Papulosquamous, Follicular & Adnexal Disease
5.1 Psoriasis: Variants, Psoriatic Arthritis, Comorbidity & European Management 5.2 Lichen Planus, Lichenoid Eruptions & Other Papulosquamous Disorders 5.3 Acne Vulgaris, Rosacea & Perioral Dermatitis 5.4 Hidradenitis Suppurativa, Hyperhidrosis & Other Sweat Gland Disorders
6 Chapter 6: Hair, Nails & Pigmentary Disorders
6.1 Hair Disorders: Non-Scarring & Scarring Alopecia, Hair Shaft Defects & Hirsutism 6.2 Nail Disorders, Onychomycosis & Nail Unit Tumours 6.3 Pigmentary Disorders: Vitiligo, Melasma & Other Hypo- and Hyperpigmentation
7 Chapter 7: Drug Reactions, Granulomatous & Deposition Disease and Skin Signs of Systemic Disease
7.1 Cutaneous Adverse Drug Reactions, SCARs & Dermatological Emergencies 7.2 Granulomatous & Deposition Disorders and Panniculitis 7.3 Skin Signs of Systemic Disease, Porphyrias, Nutritional Deficiency & Paraneoplastic Dermatoses
8 Chapter 8: Pruritus, Pregnancy & Geriatric Dermatology, Physical Injury and Mucosal Disease
8.1 Chronic Pruritus, Chronic Prurigo, Dermatoses of Pregnancy & Geriatric Dermatology 8.2 Burns, Cold, Heat & Radiation Injury and the Principles of Wound Healing 8.3 Oral Mucosal, Lip, Genital Mucosal & Perianal (Proctological) Disease
9 Chapter 9: Autoimmune Bullous Diseases
9.1 Pemphigus Group: Pemphigus Vulgaris, Foliaceus & Paraneoplastic Pemphigus 9.2 Pemphigoid Group & Epidermolysis Bullosa Acquisita 9.3 Dermatitis Herpetiformis & Linear IgA Bullous Dermatosis
10 Chapter 10: Eczematous Disorders, Urticaria & Allergology
10.1 Atopic Dermatitis: Pathogenesis, Phenotypes & European Management 10.2 Allergic & Irritant Contact Dermatitis: Pathogenesis, Investigation & Common Allergens 10.3 Urticaria, Angioedema & Cutaneous Mastocytosis 10.4 Immediate-Type Allergy: Diagnostics, Anaphylaxis, Food, Venom & Drug Allergy
11 Chapter 11: Connective Tissue Diseases & Cutaneous Vasculitis
11.1 Cutaneous Lupus Erythematosus Spectrum & Systemic Manifestations 11.2 Dermatomyositis, Systemic Sclerosis & Scleroderma Spectrum 11.3 Cutaneous Vasculitis & Neutrophilic Dermatoses
12 Chapter 12: Paediatric & Genetic Dermatology
12.1 Vascular Anomalies & Benign Neonatal Dermatoses 12.2 Hereditary Ichthyoses & Disorders of Keratinisation 12.3 Genodermatoses, Neurocutaneous Syndromes & Epidermolysis Bullosa
13 Chapter 13: Bacterial, Mycobacterial, Parasitic & Zoonotic Cutaneous Infections
13.1 Bacterial Skin & Soft Tissue Infections 13.2 Mycobacterial Infections: Cutaneous Tuberculosis, Leprosy & Atypical Mycobacteria 13.3 Parasitic Infestations, Arthropod Bites & Cutaneous Leishmaniasis 13.4 Lyme Borreliosis, Rickettsioses & Other Zoonotic and Travel-Related Skin Infections
14 Chapter 14: Viral & Fungal Cutaneous Infections
14.1 Herpesviridae Infections: HSV, VZV & HHV-8 14.2 Poxviruses & Human Papillomavirus Manifestations 14.3 Superficial, Subcutaneous & Deep Mycoses
15 Chapter 15: Sexually Transmitted Infections & Genital Infections
15.1 Syphilis: Pathogenesis, Clinical Stages, Serology & European Management 15.2 Neisseria gonorrhoeae, Chlamydia trachomatis & Genital Ulcer Diseases 15.3 HIV-Related Dermatoses, Partner Notification & Anogenital Lichen Sclerosus 15.4 Non-Gonococcal Urethritis, Mycoplasma genitalium, Trichomoniasis, Vaginal Infections & Balanitis
16 Chapter 16: Sexual Health Services, HIV Prevention & Anogenital Medicine
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP 16.2 HPV-Related Anogenital Neoplasia, Cervical Screening & Common Gynaecological and Andrological Disorders 16.3 STIs in Pregnancy, Neonates & Children, Contraception, Sexual Health & Psychosexual Problems
17 Chapter 17: Keratinocyte Carcinomas, Precancerous Lesions & Other Skin Tumours
17.1 Actinic Keratoses, Bowen Disease & Field Cancerisation 17.2 Basal Cell Carcinoma: Subtypes, Risk Stratification & Management 17.3 Cutaneous Squamous Cell Carcinoma & Keratoacanthoma 17.4 Benign & Malignant Epidermal, Adnexal, Mesenchymal and Vascular Tumours, Cysts, Histiocytoses & Metastases
18 Chapter 18: Melanocytic Naevi & Melanoma
18.1 Benign Melanocytic Naevi: Acquired, Congenital, Spitz, Blue, Halo & Atypical Naevi 18.2 Melanoma Risk Factors, Clinical Presentation & Biopsy Protocol 18.3 Melanoma Histopathology, Breslow Thickness & Staging 18.4 Systemic Therapy for Advanced & Metastatic Melanoma
19 Chapter 19: Dermoscopy, Skin Imaging & Cutaneous Lymphomas
19.1 Dermoscopic Principles, Structures & Algorithmic Approaches 19.2 Dermoscopy of Non-Melanocytic Cutaneous Neoplasms 19.3 Non-Invasive Skin Imaging, Skin Function Measurement, Teledermatology & Skin Cancer Surveillance 19.4 Cutaneous Lymphomas, Merkel Cell Carcinoma & Cutaneous Sarcomas
20 Chapter 20: Dermatopharmacology, Systemic Therapeutics & Prescribing
20.1 Topical Corticosteroids, Calcineurin Inhibitors & Retinoids 20.2 Systemic Immunosuppressive & Biologic Therapies 20.3 Oral Retinoids & Phototherapy Modalities 20.4 Dermatological Prescribing: Anti-Infectives, Antihistamines, Antimalarials, Dapsone, Special Populations & Cutaneous Toxicity of Cancer Therapy
21 Chapter 21: Dermatosurgery, Cryotherapy, Lasers & Aesthetic Procedures
21.1 Surgical Anatomy, Local Anaesthesia & Excision Principles 21.2 Cutaneous Reconstructive Flaps, Skin Grafts & Surgical Complications 21.3 Cryosurgery, Electrosurgery & Cutaneous Lasers 21.4 Aesthetic & Corrective Dermatology, Photodynamic Therapy & Dermatological Radiotherapy
22 Chapter 22: Phlebology, Angiology, Psychodermatology & EBDVD Revision
22.1 Phlebology, Chronic Venous Insufficiency & Lower Extremity Ulcers 22.2 Angiology: Arterial Disease, Raynaud Phenomenon, Livedo, Thrombosis, Lymphoedema & Lipoedema 22.3 Psychodermatology, Delusional Infestation & Factitious Disorders 22.4 EBDVD Revision Strategy & Cross-Topic Review
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP
Key Takeaways Explain This Topic AI
Chlamydia is the most frequently reported bacterial STI in the EU/EEA, and reported gonorrhoea and syphilis have risen markedly over the past decade, especially among men who have sex with men.
A fourth-generation HIV antigen/antibody test detects most infections by about 4 weeks, and a negative result 6 weeks after the last exposure is widely used to exclude infection.
European (EACS) guidance recommends antiretroviral therapy for everyone with HIV as soon as possible, regardless of CD4 count, and a sustained undetectable viral load prevents sexual transmission (U=U).
Event-driven HIV PrEP with tenofovir disoproxil/emtricitabine (two tablets 2 to 24 hours before sex, then one at 24 and 48 hours) is recommended only for men who have sex with men.
HIV post-exposure prophylaxis should start as soon as possible and within 72 hours of exposure, and it consists of a 28-day course of three antiretroviral drugs.
Last updated: September 2026
16.1 STI Epidemiology, Prevention, Services, Sexual History, HIV Testing, ART & PrEP/PEP
The official venereology syllabus starts with epidemiology of STIs including HIV , prevention and control including partner notification , organisation of STI services , and sexual history-taking and genito-anal examination , and it includes HIV infection and its management . In many continental European countries, venereology is part of dermatology training, so dermatologists run STI clinics.
Epidemiology in the EU/EEA
The European Centre for Disease Prevention and Control (ECDC) collects national surveillance data.
- Infection Recent European Pattern
- Chlamydia The most frequently reported bacterial STI; highest rates in young women and men under 25
Gonorrhoea Marked rise over the past decade; many cases in men who have sex with men (MSM), with increases in young heterosexuals in some countries; growing antimicrobial resistance
- Syphilis Rising, mostly among MSM; congenital syphilis is rare but has increased in some countries
- Lymphogranuloma venereum Mostly MSM, often with HIV, presenting as proctitis
HIV Roughly 20,000–25,000 new diagnoses a year across the EU/EEA in recent years, with about half diagnosed late (CD4 count below 350 cells/µL)
Reporting of syphilis, gonorrhoea, and HIV to national authorities is mandatory in most European countries. Rising rates are linked to changes in sexual behaviour, dating apps, chemsex , lower condom use, and better testing.
Prevention and Control
Level Measures
Primary (prevent infection) Sex education; condoms; vaccination against HPV, hepatitis B, and hepatitis A (and mpox for at-risk groups); HIV PrEP ; treating people with HIV to an undetectable viral load
Secondary (find and treat early) Screening of at-risk groups; rapid diagnosis and treatment; partner notification ; test of cure where recommended
Tertiary (limit complications) Prevent PID, infertility, neurosyphilis, congenital infection, and cancer
Doxycycline post-exposure prophylaxis (doxy-PEP, 200 mg within 72 hours after condomless sex) reduces syphilis and chlamydia in MSM and transgender women with recurrent STIs. European bodies are cautious because of the risk of resistance in gonorrhoea and other bacteria, and they suggest limited, individual use rather than routine use.
Organisation of STI Services
Good STI care is open access , confidential , often free at the point of use , and ideally one-stop (testing, treatment, partner notification, vaccination, contraception, and PrEP in one place). Models include specialist dermato-venereology and sexual health clinics, express testing for people without symptoms, online and home-sampling services, and outreach to MSM, sex workers, migrants, and people who inject drugs . Services need links to HIV care, gynaecology, urology, paediatrics, and safeguarding teams.
Sexual History
A structured history makes sure the right tests are taken from the right sites:
Symptoms : discharge, dysuria, ulcers, rash, anal or pharyngeal symptoms, and their duration.
Last sexual contact and previous partners in the relevant window: gender, regular or casual, and whether they can be contacted.
Sites and practices : oral, vaginal, and anal (insertive or receptive) sex, and condom use.
Previous STIs and HIV tests , vaccination status, and PrEP use.
Contraception and possible pregnancy.
Risk factors : drug use and chemsex (GHB/GBL, mephedrone, methamphetamine), sex work, travel, partners from high-prevalence areas.
Safeguarding : age, coercion, sexual exploitation, and intimate partner violence.
Genito-Anal Examination and Sampling
Explain the examination, obtain consent, and offer a chaperone .
Examine the skin, mouth, and lymph nodes. In men, retract the foreskin and inspect the urethral meatus, scrotum, and perianal skin. In women, examine the vulva and use a speculum (cervix, vaginal walls), with bimanual examination if PID is suspected. Use proctoscopy after receptive anal sex with symptoms.
Test Best Sample
Gonorrhoea and chlamydia NAAT Men: first-void urine ; women: vulvovaginal swab (self-taken is acceptable); rectal and pharyngeal swabs according to exposure (routine for MSM)
- Gonorrhoea culture Urethral, cervical, rectal, or pharyngeal swab before treatment, for susceptibility testing
- Herpes simplex virus PCR swab from an ulcer
- Syphilis Serology; PCR or darkfield microscopy of a lesion
HIV and hepatitis Blood: HIV antigen/antibody, hepatitis B (HBsAg, anti-HBc), and hepatitis C antibodies where there is risk
HIV Testing
Fourth-generation laboratory tests detect p24 antigen and antibody . They pick up most infections by about 4 weeks, and a negative result 6 weeks after the last exposure is widely used to exclude infection. Rapid point-of-care and self-tests mostly detect antibody only and have a longer window.
A reactive result is confirmed with a second assay (and viral load). Give results in person with support.
Offer testing widely. Opt-out testing in STI clinics and antenatal care, and testing whenever an HIV indicator condition is present. European initiatives recommend testing for conditions where undiagnosed HIV prevalence exceeds about 0.1%. Dermatological examples include any STI , herpes zoster (especially multidermatomal or in younger adults), severe or recalcitrant seborrhoeic dermatitis or psoriasis , oral candidiasis, oral hairy leukoplakia , Kaposi sarcoma , hepatitis B or C, a mononucleosis-like illness, lymphoma, and cervical or anal dysplasia.
Principles of Antiretroviral Therapy (ART)
The European AIDS Clinical Society ( EACS ) recommends ART for everyone with HIV as soon as possible , regardless of CD4 count. Same-day starts are possible.
First-line regimens usually combine an integrase inhibitor (dolutegravir or bictegravir) with two nucleoside reverse transcriptase inhibitors (tenofovir with emtricitabine or lamivudine). Dual therapy with dolutegravir and lamivudine suits selected patients. Long-acting injectable cabotegravir with rilpivirine is an option for people who are already suppressed.
U=U (undetectable = untransmittable): people with a sustained undetectable viral load do not transmit HIV sexually.
Dermatology-relevant points: abacavir hypersensitivity (screen for HLA-B*57:01 first); rashes with nevirapine and some other drugs; drug interactions with boosters (ritonavir, cobicistat), for example inhaled or injected corticosteroids causing Cushing syndrome, and interactions with azoles, ciclosporin, and some biologics or small molecules; and immune reconstitution inflammatory syndrome after starting ART (herpes zoster, Kaposi sarcoma flares, folliculitis).
HIV Pre-Exposure Prophylaxis (PrEP)
Aspect Key Points
Who People at substantial risk: MSM and transgender women with condomless anal sex, partners of people with detectable HIV, and others at high risk
Oral daily PrEP Tenofovir disoproxil/emtricitabine once daily; suitable for all genders
Event-driven ("2-1-1") PrEP Two tablets 2–24 hours before sex, then one at 24 hours and one at 48 hours; only for MSM , and not for people with hepatitis B
- Long-acting PrEP Injectable cabotegravir every 2 months is approved in the EU
- Before starting Exclude HIV (including acute infection), check kidney function and hepatitis B status
- Follow-up HIV and STI testing every 3 months , kidney function, adherence, hepatitis B vaccination
- HIV Post-Exposure Prophylaxis (PEP)
Start as soon as possible, ideally within hours and no later than 72 hours after exposure.
A 28-day course of three antiretroviral drugs (for example tenofovir/emtricitabine plus an integrase inhibitor).
Indications depend on the exposure and the source. For example, PEP is recommended after receptive anal sex with a partner with HIV and a detectable or unknown viral load. It is usually not needed if the source has a confirmed undetectable viral load.
Test for HIV at baseline and again after the course, and consider hepatitis B vaccination or immunoglobulin and emergency contraception.